LTS Lohmann在2025年11月30日之前购买美国CDMO文艺复兴组织Lakewood,加上鼻喷和注射能力。 LTS Lohmann to acquire U.S. CDMO Renaissance Lakewood, adding nasal spray and injectable capabilities before Nov. 30, 2025.

LTS LOHMANN Therapie-Systeme AG宣布,它将收购美国一家专门处理鼻喷剂和消毒注射器的CDMO,即Renisesance Lakewood, 并扩大其全球制造网络。 LTS LOHMANN Therapie-Systeme AG has announced it will acquire Renaissance Lakewood, a U.S. CDMO specializing in nasal sprays and sterile injectables, expanding its global manufacturing network. 这项交易有待监管批准,预计将在2025年11月30日前结束。 The deal, pending regulatory approval, is expected to close before November 30, 2025. 美国新泽西州莱克伍德的Renaissance设施将增加单剂量,双剂量和多剂量鼻喷雾剂的功能,以及小型的肠道填充服务和研发实验室. Renaissance’s Lakewood, New Jersey, facilities will add capabilities in unit-dose, bi-dose, and multi-dose nasal sprays, along with small-volume parenteral fill-finish services and R&D labs. 收购将增加约500名员工,并加强LTS在创新药物交付方面的地位, 补充其在皮肤贴片,口腔薄膜和可穿戴设备方面的现有专业知识. The acquisition brings approximately 500 employees and strengthens LTS’s position in innovative drug delivery, complementing its existing expertise in transdermal patches, oral thin films, and wearable devices. 两家公司都引述了创新、质量和以病人为中心的解决方案的共同价值观。 Both companies cited shared values in innovation, quality, and patient-centered solutions.